IDEAYA Biosciences Advances IDE849 into Phase 3 Trial for Extensive Stage Small Cell Lung Cancer — IDEAYA Biosciences, Inc.

Event summary

IDEAYA Biosciences plans to initiate a Phase 3 registrational trial for IDE849 by year-end 2026, targeting extensive stage small cell lung cancer (ES-SCLC).
The trial will enroll approximately 400 patients, randomized 1:1 between IDE849 monotherapy and investigator's choice of topotecan or ambrucin.
Primary endpoints include overall response rate (ORR) for accelerated approval and median overall survival for full approval.
IDE849 is also being evaluated in combination studies with AstraZeneca's Imfinzi and IDEAYA's PARG inhibitor IDE161 for potential first-line SCLC treatment.

The big picture

IDEAYA Biosciences is positioning IDE849 as a potential best-in-class therapy for ES-SCLC, a disease with significant unmet medical need. The company's strategy of combining IDE849 with other targeted therapies aims to enhance its pipeline's durability and address broader oncology markets. The successful FDA Type C meeting clears a critical regulatory hurdle, but the path to approval will depend on the trial's execution and clinical outcomes.

What we're watching

Regulatory Pathway: Whether the FDA's feedback will support the proposed Phase 3 trial design and endpoints for both accelerated and full approval.
Clinical Efficacy: The pace at which IDE849 demonstrates a best-in-class profile in ES-SCLC and neuroendocrine carcinomas (NEC) based on upcoming data updates.
Combination Strategy: How the combination of IDE849 with Imfinzi and IDE161 will impact the potential first-line SCLC Phase 3 registrational trial design.